Skip to content

Mounjaro vs Ozempic: how do they compare?

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Mounjaro vs Ozempic compares two weekly injections, both FDA-approved for adults with type 2 diabetes. Mounjaro (tirzepatide) is also approved for children 10 and older. Ozempic (semaglutide) also has a kidney use and a tablet. Manufacturer self-pay is $499 a month for Mounjaro at any strength and $349 for Ozempic 1 mg, or $499 for 2 mg.

Source: LillyDirect self-pay

Key takeaways

  • Both are approved for type 2 diabetes. Neither is approved for weight reduction.
  • Only the Ozempic injection has a kidney use, in adults with type 2 diabetes and chronic kidney disease.
  • Only Mounjaro is approved from age 10 for blood sugar control in type 2 diabetes.
  • Paying cash? Ozempic 1 mg is $349 a month through NovoCare. Mounjaro is $499 through LillyDirect at any strength.
  • One 40-week trial on the Mounjaro label tested it against semaglutide 1 mg, not Ozempic's top dose.

Mounjaro vs Ozempic, side by side

From each FDA label and our verified price records
MounjaroOzempic
Active ingredienttirzepatidesemaglutide
MakerEli Lilly and CompanyNovo Nordisk
FDA-approved uses
  • adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus
  • reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (injection and tablets)
  • Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease (injection)
  • Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events (tablets)
  • Reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease (injection)
How it is takenweekly (multi-dose pen); weekly (multi-dose vial); weekly (single-dose pen); weekly (single-dose vial)weekly (multi-dose pen); daily (tablet)
Strengths2.5 to 15 mg0.25 to 9 mg
Label starting dose
  • 2.5 mg weekly
  • 0.25 mg weekly
  • 1.5 mg daily
Cheapest verified self-pay$499 per fill at 15 mg
LillyDirect self-pay
No self-pay price listed
With covering commercial insurance$25 with the manufacturer cardNo savings-card price listed
Medicare GLP-1 BridgeNoNo
LabelRevised: 8/2026 (DailyMed version 40)Revised: 5/2026 (DailyMed version 20)
Mounjaro: most common reactions on the label · Pool of two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 monotherapy and SURPASS-5 added to basal insulin with or without metformin); 718 patients exposed to Mounjaro for a mean of 36.6 weeks. Hypoglycemia is not included.
Reaction15 mgPlacebo
Nausea18%4%
Diarrhea17%9%
Decreased Appetite11%1%
Vomiting9%2%
Constipation7%1%
Dyspepsia5%3%
Ozempic: most common reactions on the label · Adults with type 2 diabetes in 2 placebo-controlled trials (1 monotherapy trial and 1 trial in combination with basal insulin); mean duration of exposure to Ozempic was 32.9 weeks. The table excludes hypoglycemia.
ReactionOzempic 1 mgPlacebo
Nausea20.3%6.1%
Vomiting9.2%2.3%
Diarrhea8.8%1.9%
Abdominal pain5.7%4.6%
Constipation3.1%1.5%

Each table comes from that medicine's own trials. The trials differ in who was studied and for how long, so the percentages are not a head-to-head comparison.

Mounjaro and Ozempic are the two most-searched weekly injections for type 2 diabetes. They’re different molecules from different companies: Mounjaro is tirzepatide from Eli Lilly, and Ozempic is semaglutide from Novo Nordisk. This pair is unusual, because a trial that tested one against the other appears on a label, so this page can report it.

Which one suits whom?

  • You have type 2 diabetes and chronic kidney disease. The Ozempic injection is approved to reduce the risk of sustained eGFR decline (a lasting drop in a measure of kidney function), end-stage kidney disease and cardiovascular death in that group. Mounjaro’s label has no kidney use.
  • The patient is aged 10 to 17 with type 2 diabetes. Mounjaro is approved for blood sugar control from age 10. Ozempic’s approved uses are in adults.
  • You want a tablet. Ozempic has a once-daily tablet on a separate label. Mounjaro is an injection only.
  • You’re paying cash. Ozempic’s self-pay price is lower at 0.25 mg, 0.5 mg and 1 mg, and equal to Mounjaro’s at 2 mg.

Both labels also have a cardiovascular use, worded differently, as the next section explains. If you’re choosing with your prescriber, three questions help: does your kidney health change the picture, which brand does your plan prefer, and what dose are you likely to end up on? That last one decides whether the two cost the same in cash.

What is each one approved for?

Both are approved, alongside diet and exercise, to improve blood sugar control in type 2 diabetes: Mounjaro in adults and in children 10 years of age and older, Ozempic in adults.

Cardiovascular risk. Mounjaro is approved to reduce the risk of major adverse cardiovascular events (serious heart and blood vessel events) in adults with type 2 diabetes who are at high risk for these events. The Ozempic injection is approved for the same outcome in adults with type 2 diabetes and established cardiovascular disease. The evidence behind each comes from a different kind of trial. Ozempic’s SUSTAIN 6 trial compared it with placebo in 3,297 patients over a median of 2.1 years and found a hazard ratio (how the rate of events compared between the two groups) of 0.74 for major adverse cardiovascular events. Mounjaro’s outcomes trial compared it with dulaglutide over a median of 210.1 weeks. Mounjaro was non-inferior (not shown to be worse), with a hazard ratio of 0.92, and superiority to dulaglutide was not established. A placebo comparison and an active comparison can’t be read against each other.

Kidney disease. Only the Ozempic injection has this use. In the FLOW trial of 3,533 patients with type 2 diabetes and chronic kidney disease, Ozempic 1 mg reduced the primary kidney composite endpoint (the trial’s combined measure of kidney outcomes), with a hazard ratio of 0.76.

Neither is approved for weight reduction.

What does the head-to-head trial on the label say?

The Mounjaro label reports a 40-week trial of Mounjaro versus semaglutide 1 mg in adults with type 2 diabetes, added to metformin. The label table gives the change in HbA1c (a measure of average blood sugar over recent months) at week 40:

  • semaglutide 1 mg: -1.9
  • Mounjaro 5 mg: -2.0
  • Mounjaro 10 mg: -2.2
  • Mounjaro 15 mg: -2.3

HbA1c is measured in percentage points. We report these four values exactly as our label record holds them, and we add nothing to them. Three limits are worth knowing. The comparison dose was 1 mg, and the Ozempic pen goes up to 2 mg. The trial was in people already taking metformin. And an average across a trial group doesn’t tell you how you’ll respond or which medicine you’ll tolerate.

How do the doses and devices compare?

Both are injected once weekly, at any time of day, with or without meals, under the skin of the abdomen, thigh or upper arm (for Mounjaro, the upper arm only when another person gives the injection).

Mounjaro comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. It starts at 2.5 mg. If more blood sugar control is needed, the dose rises in 2.5 mg steps after at least 4 weeks on the current dose, to a maximum of 15 mg in adults.

Ozempic comes in 0.25 mg, 0.5 mg, 1 mg, 2 mg. It starts at 0.25 mg for 4 weeks, then 0.5 mg, and may go to 1 mg and 2 mg if more blood sugar control is needed, with at least 4 weeks at each step.

The pens work differently. The Mounjaro prices in our records are for the single-dose pen: one pen per weekly dose, four to a carton. The Ozempic pen is multi-dose: one pen covers four weekly doses at a steady dose, needles are included, and the pen must never be shared, even with a new needle. If you also use insulin, both labels say to give it as a separate injection and never mix the two. The dosing guide and the titration schedule tool lay out each ladder.

What does each one cost?

Here are the prices on each route:

Mounjaro. LillyDirect self-pay starts at $499 a month, the same at every strength. The list price (the full price before any discount) is $1,112.16 per fill. The savings card lowers a covered fill to as little as $25, and sets a fill at $499 when a commercial plan doesn’t cover it.

Ozempic. NovoCare self-pay is $199 a month for a new patient’s first two fills of 0.25 mg or 0.5 mg, then $349. The 1 mg pen is $349 and the 2 mg pen is $499. The list price is $1,027.51 per pen. The savings offer lowers a covered fill to as little as $25.

A full year on self-pay comes to $6,487 for Mounjaro at any strength, $4,537 for Ozempic 1 mg and $6,487 for Ozempic 2 mg. The cost calculator prices other dose paths. The Mounjaro cost and Ozempic cost pages list every route and its conditions, and the savings card guide compares the manufacturer cards.

How do insurance and Medicare treat them?

Commercial plans. Both are diabetes medicines and both are widely listed, usually with conditions: prior authorization (the plan’s approval before it pays), proof of a type 2 diabetes diagnosis, or a requirement to try another medicine first. Plans often prefer one over the other. Call the number on your insurance card and ask which is on the formulary (the plan’s list of covered drugs) and at what tier (the cost level your plan sets). The prior authorization guide explains the paperwork.

Medicare. CMS states that type 2 diabetes is an indication eligible for Part D coverage, so both run through your Part D plan. Neither is in the Medicare GLP-1 Bridge. One scheduled change affects Ozempic only. Under the Medicare Drug Price Negotiation Program, CMS and Novo Nordisk agreed a negotiated price of $274 for a 30-day supply of semaglutide (Ozempic, Rybelsus, Wegovy) for 2027, against a 2024 list price of $959, a 71% discount. What you pay still depends on your plan’s cost sharing. See the Medicare hub and Part D costs.

How do the side effects compare?

Both labels carry a boxed warning about the risk of thyroid C-cell tumors, and both list gastrointestinal (stomach and bowel) reactions as the most common. The tables below come from each drug’s own placebo-controlled trials. They weren’t collected in the head-to-head trial, so they aren’t a ranking.

Mounjaro. In a pool of two placebo-controlled trials in adults with type 2 diabetes (mean exposure 36.6 weeks), nausea was reported by 12, 15 and 18 percent of patients on 5 mg, 10 mg and 15 mg, against 4 percent on placebo. Diarrhea was reported by 12, 13 and 17 percent (placebo 9 percent) and vomiting by 5, 5 and 9 percent (placebo 2 percent). Gastrointestinal reactions led 3.0%, 5.4% and 6.6% of patients on the three doses to stop treatment, versus 0.4% on placebo.

Ozempic. In two placebo-controlled trials in adults with type 2 diabetes (mean exposure 32.9 weeks), nausea was reported by 15.8 percent of patients on 0.5 mg and 20.3 percent on 1 mg, against 6.1 percent on placebo. Diarrhea was reported by 8.5 percent and 8.8 percent (placebo 1.9 percent) and vomiting by 5 percent and 9.2 percent (placebo 2.3 percent). Gastrointestinal reactions led 3.1% and 3.8% of patients to stop treatment, versus 0.4% on placebo.

Both labels warn that low blood sugar is more likely when the medicine is combined with insulin or a sulfonylurea (a type of diabetes medicine), and say the prescriber should consider reducing the dose of that other medicine. The Ozempic label also has a warning on diabetic retinopathy complications (eye problems from diabetes). In a 2-year trial, they occurred in 3.0% of patients on Ozempic and 1.8% on placebo. Ask your prescriber what this warning means for you. Full tables for both drugs are on this page.

Switching between Mounjaro and Ozempic

Neither label tells you how to move from the other drug. The Mounjaro label gives no instructions for switching from another GLP-1 medicine, only its starting dose. The Ozempic injection label is the same. No label converts between semaglutide and tirzepatide doses, so we don’t publish a conversion.

A switch replaces one medicine with the other. It doesn’t add a second one. The label for Zepbound, Lilly’s other tirzepatide brand, says coadministration of Zepbound with any GLP-1 receptor agonist is not recommended. Your prescriber decides where you start on the new medicine and when the old one stops. Our page on switching from Ozempic to Mounjaro sets out what each label says, and the switching planner compares the cost before and after.

Frequently asked questions

Is Mounjaro stronger than Ozempic?

The Mounjaro label records one trial against semaglutide 1 mg, in adults with type 2 diabetes on metformin. At week 40, HbA1c changed by -2.0, -2.2 and -2.3 with Mounjaro 5 mg, 10 mg and 15 mg, and by -1.9 with semaglutide 1 mg. That's what the label table states. It didn't test Ozempic's 2 mg dose, and it doesn't predict an individual result.

Which is cheaper, Mounjaro or Ozempic?

On manufacturer self-pay, Ozempic is lower at most doses. New patients pay $199 a month for the first two fills of 0.25 mg or 0.5 mg, then $349. The 1 mg pen is $349 and the 2 mg pen is $499. Mounjaro is $499 a month at every strength. With commercial insurance that covers the drug, both savings cards go as low as $25.

Ozempic vs Mounjaro: what is the difference?

They contain different molecules: Mounjaro is tirzepatide from Eli Lilly and Ozempic is semaglutide from Novo Nordisk. Both are weekly injections approved for type 2 diabetes. Mounjaro comes in six strengths up to 15 mg and is approved from age 10. Ozempic comes in four pen doses up to 2 mg, has a kidney use, and also comes as a daily tablet.

Can I switch from Ozempic to Mounjaro?

Your prescriber can switch you, but the Mounjaro label gives no instructions for coming from another GLP-1 medicine. It gives only its starting dose, 2.5 mg once weekly. No label converts an Ozempic dose into a Mounjaro dose, and a switch replaces one medicine with the other. Your prescriber decides the starting point and timing.

Does Medicare cover Mounjaro and Ozempic?

CMS lists type 2 diabetes as an indication eligible for Part D coverage, so both go through your Part D plan's formulary and rules. Neither is a product of the Medicare GLP-1 Bridge, which is for weight management. For 2027, CMS and Novo Nordisk agreed a negotiated Medicare price of $274 for a 30-day supply of semaglutide, which includes Ozempic.

Are Mounjaro or Ozempic approved for weight loss?

No. Neither label has a weight-reduction use. Both are approved for type 2 diabetes. The brands labeled for long-term weight reduction are Zepbound, which contains tirzepatide, and Wegovy, which contains semaglutide. Each of those has its own label, doses and prices, and insurers treat them as separate drugs.

Sources (26)

  1. 1.
    FDA label (DailyMed): Mounjaro prescribing information, section 14.3, Table 5
    “Table 5: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1 mg in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin. HbA1c (%) - Change at Week 40: Semaglutide 1 mg: -1.9; MOUNJARO 5 mg: -2.0; MOUNJARO 10 mg: -2.2; MOUNJARO 15 mg: -2.3”
  2. 2.
    FDA label (DailyMed): Mounjaro prescribing information, section 14.6
    “Over a median follow-up of 210.1 weeks, MOUNJARO was non-inferior to dulaglutide for reducing the occurrence of MACE-3. The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for MOUNJARO compared to dulaglutide. Superiority to dulaglutide was not established.”
  3. 3.
    FDA label (DailyMed): Ozempic prescribing information, section 14.2
    “OZEMPIC significantly reduced the occurrence of MACE. The estimated hazard ratio for time to first MACE was 0.74 (95% CI: 0.58, 0.95).”
  4. 4.
    FDA label (DailyMed): Ozempic prescribing information, section 14.3
    “OZEMPIC was superior to placebo in reducing the incidence of the primary composite endpoint of a sustained decline in eGFR of ≥50%, sustained eGFR <15 mL/min/1.73m2, chronic renal replacement therapy, renal death, CV death (HR 0.76 [95% CI 0.66, 0.88], p=0.0003) as shown in Table 10 and Figure 7.”
  5. 5.
    FDA label (DailyMed): Mounjaro prescribing information, section 2.2
    “Administer MOUNJARO once weekly, any time of day, with or without meals.”
  6. 6.
    FDA label (DailyMed): Ozempic prescribing information, section 2.1
    “Administer OZEMPIC once weekly, on the same day each week, at any time of the day, with or without meals.”
  7. 7.
    FDA label (DailyMed): Mounjaro prescribing information, section 2.2
    “Inject MOUNJARO subcutaneously in the abdomen, thigh, or have another person inject MOUNJARO in the back of the upper arm. Rotate injection sites with each dose.”
  8. 8.
    FDA label (DailyMed): Ozempic prescribing information, section 2.1
    “Inject OZEMPIC subcutaneously in the abdomen, thigh, or upper arm. Instruct patients to use a different injection site each week when injecting in the same body region.”
  9. 9.
    FDA label (DailyMed): Ozempic prescribing information, section 3
    “Injection: 2 mg/3 mL (0.68 mg/mL) for 4 doses of 0.25 mg and 2 doses of 0.5 mg or 4 doses of 0.5 mg, 4 mg/3 mL (1.34 mg/mL) for 4 doses of 1 mg, and 8 mg/3 mL (2.68 mg/mL) for 4 doses of 2 mg in single-patient-use pens”
  10. 10.
    FDA label (DailyMed): Ozempic prescribing information, Instructions for Use
    “NovoFine® Plus 32G 4 mm disposable needles are included with your OZEMPIC pen.”
  11. 11.
    FDA label (DailyMed): Ozempic prescribing information, section 16
    “Each OZEMPIC multi-dose pen is for use by a single patient. An OZEMPIC pen must never be shared between patients, even if the needle is changed”
  12. 12.
    FDA label (DailyMed): Mounjaro prescribing information, section 2.2
    “When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.”
  13. 13.
    FDA label (DailyMed): Ozempic prescribing information, section 2.1
    “When using OZEMPIC with insulin, instruct patients to administer as separate injections and to never mix the products. It is acceptable to inject OZEMPIC and insulin in the same body region, but the injections should not be adjacent to each other.”
  14. 14.
    FDA label (DailyMed): Mounjaro prescribing information, section 7.1
    “When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].”
  15. 15.
    FDA label (DailyMed): Ozempic prescribing information, section 7.1
    “When initiating OZEMPIC, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia”
  16. 16.
    FDA label (DailyMed): Mounjaro prescribing information, section 8.4
    “The safety and effectiveness of MOUNJARO have not been established in pediatric patients less than 10 years of age.”
  17. 17.
    FDA label (DailyMed): Zepbound prescribing information, section 1
    “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  18. 18.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  19. 19.
    CMS: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027
    “Below is the list of negotiated prices, which the statute refers to as maximum fair prices (MFPs), for the 15 selected drugs covered under Medicare Part D that will go into effect beginning January 1, 2027, based on negotiations and agreements reached between CMS and participating drug companies. [table] Drug Name: Ozempic; Rybelsus; Wegovy. Participating Drug Company: Novo Nordisk Inc. Agreed to Negotiated Price for 30-day Supply for CY 2027: $274. List Price for 30-day Supply, CY 2024: $959. Discount of Negotiated Price from 2024 List Price: 71%.”
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.